GH Research (GHRS)

• Market cap: $1.17B
• 1 day: 7.66%
• 5 days: -5.55%
• 1 month: 51.23%
• 3 months: 21.99%
• 6 months: 45.16%
• Year to date: 52.95%
• 1 year: 113.16%
• 5 years: 5.19%
• 10 years: 5.19%
• Sector: Healthcare
• Industry: Biotechnology

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Employees: 56